Float Short %

10.71

Margin Of Safety %

Put/Call OI Ratio

1.57

EPS Next Q Diff

0.04

EPS Last/This Y

0.08

EPS This/Next Y

Price

1.21

Target Price

6.4

Analyst Recom

2.11

Performance Q

-41.83

Relative Volume

0.89

Beta

1.65

Ticker: ZNTL

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-04-14	ZNTL	1.22	0.81	0.00	1511
2025-04-15	ZNTL	1.275	0.81	0.00	1511
2025-04-16	ZNTL	1.265	0.81	0.00	1511
2025-04-17	ZNTL	1.3	0.81	0.00	1511
2025-04-18	ZNTL	1.29	0.81	1.67	1512
2025-04-21	ZNTL	1.36	2.03	0.00	897
2025-04-22	ZNTL	1.465	2.02	10.00	898
2025-04-23	ZNTL	1.495	2.02	10.00	898
2025-04-24	ZNTL	1.515	2.02	10.00	898
2025-04-25	ZNTL	1.43	2.0538720538721	0	907
2025-04-28	ZNTL	1.42	2.0538720538721	0	907
2025-04-29	ZNTL	1.37	2.05	0.00	907
2025-04-30	ZNTL	1.41	2.05	0.00	907
2025-05-01	ZNTL	1.455	1.58	0.00	997
2025-05-02	ZNTL	1.445	1.57	0.00	998
2025-05-05	ZNTL	1.365	1.57	0.00	998
2025-05-06	ZNTL	1.24	1.57	0.00	998
2025-05-07	ZNTL	1.23	1.57	0.00	998
2025-05-08	ZNTL	1.26	1.57	10.00	999
2025-05-09	ZNTL	1.225	1.57	10.00	999
2025-05-12	ZNTL	1.285	1.57	10.00	999
2025-05-13	ZNTL	1.21	1.57	10.00	999
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-04-14	ZNTL	1.22	-533.5	-	-2.25
2025-04-15	ZNTL	1.27	-533.5	-	-2.25
2025-04-16	ZNTL	1.27	-533.5	-	-2.25
2025-04-17	ZNTL	1.29	-533.5	-	-2.25
2025-04-18	ZNTL	1.29	-533.5	-	-2.25
2025-04-21	ZNTL	1.36	-533.5	-	-2.25
2025-04-22	ZNTL	1.47	-533.5	-	-2.25
2025-04-23	ZNTL	1.50	-533.5	-	-2.25
2025-04-24	ZNTL	1.51	-533.5	-	-2.25
2025-04-25	ZNTL	1.43	-533.5	-	-2.25
2025-04-28	ZNTL	1.42	-533.5	-	-2.25
2025-04-29	ZNTL	1.37	-533.5	-	-2.25
2025-04-30	ZNTL	1.42	-533.5	-	-2.25
2025-05-01	ZNTL	1.45	-533.5	-	-2.25
2025-05-02	ZNTL	1.45	-533.5	-	-2.25
2025-05-05	ZNTL	1.36	-533.5	-	-2.25
2025-05-06	ZNTL	1.24	-533.5	-	-2.25
2025-05-07	ZNTL	1.23	-533.5	-	-2.25
2025-05-08	ZNTL	1.26	-533.5	-	-2.25
2025-05-09	ZNTL	1.23	-533.5	-	-2.25
2025-05-12	ZNTL	1.29	-533.5	-	-2.25
2025-05-13	ZNTL	1.21	-533.5	-	-2.25
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-04-14	ZNTL	0.50	-6.63	8.83
2025-04-15	ZNTL	0.50	-6.63	8.83
2025-04-16	ZNTL	0.50	-6.63	8.83
2025-04-17	ZNTL	0.50	-6.63	8.83
2025-04-18	ZNTL	0.50	-6.63	8.83
2025-04-21	ZNTL	0.50	-6.91	8.83
2025-04-22	ZNTL	0.50	-6.91	8.83
2025-04-23	ZNTL	0.50	-6.91	8.83
2025-04-24	ZNTL	0.50	-6.91	8.83
2025-04-25	ZNTL	0.50	-6.91	8.83
2025-04-28	ZNTL	0.50	-7.20	9.75
2025-04-29	ZNTL	0.50	-7.20	9.75
2025-04-30	ZNTL	0.50	-7.20	9.75
2025-05-01	ZNTL	0.62	-7.20	9.75
2025-05-02	ZNTL	0.62	-7.20	9.75
2025-05-05	ZNTL	0.62	-7.47	9.73
2025-05-06	ZNTL	0.62	-7.47	9.73
2025-05-07	ZNTL	0.62	-7.47	9.73
2025-05-08	ZNTL	0.62	-7.47	9.74
2025-05-09	ZNTL	0.62	-7.47	9.74
2025-05-12	ZNTL	0.62	-5.41	10.71
2025-05-13	ZNTL	0.63	-5.41	10.71
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.66

Avg. EPS Est. Current Quarter

-0.62

Avg. EPS Est. Next Quarter

-0.62

Insider Transactions

0.63

Institutional Transactions

-5.41

Beta

1.65

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

98.6

Max Drawdown 5-Year %

-98.8

Target Price

6.4

P/E

Forward P/E

PEG

P/S

1.29

P/B

0.26

P/Free Cash Flow

EPS

-2.33

Average EPS Est. Cur. Y

-2.25

EPS Next Y. (Est.)

-2.25

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-245.96

Relative Volume

0.89

Return on Equity vs Sector %

-72.9

Return on Equity vs Industry %

-55.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.21

EBIT Estimation

Zentalis Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 166

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, for the treatment of advanced solid tumors and hematological malignancies. It is in a Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; a Phase 2 clinical trial in Cyclin E1-driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; a Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; a Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, peritoneal, or fallopian tube cancer; a Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; a Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and a Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's product pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; and Dana-Farber. The company was incorporated in 2014 and is headquartered in New York, New York.

stock quote shares ZNTL – Zentalis Pharmaceuticals, Inc. Stock Price stock today

news today ZNTL – Zentalis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ZNTL – Zentalis Pharmaceuticals, Inc. yahoo finance google finance

stock history ZNTL – Zentalis Pharmaceuticals, Inc. invest stock market

stock prices ZNTL premarket after hours

ticker ZNTL fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ZNTL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y